Thymosin Beta 4: A Potential Novel Therapy for Neurotrophic Keratopathy, Dry Eye, and Ocular Surface Diseases.
Vitam Horm. 2016.
PMID: 27450739
Review.
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2012 | 1 |
| 2015 | 4 |
| 2016 | 2 |
| 2018 | 3 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Search Results
16 results
Results by year
Citations
2
articles
found by citation matching
Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.
Clin Ophthalmol. 2015.
PMID: 26056426
Free PMC article.
Search results
Page 1
Identification of glutamine as a potential therapeutic target in dry eye disease.
Signal Transduct Target Ther. 2025 Jan 22;10(1):27. doi: 10.1038/s41392-024-02119-1.
Signal Transduct Target Ther. 2025.
PMID: 39837870
Free PMC article.
Dry eye disease (DED) is a prevalent inflammatory condition significantly impacting quality of life, yet lacks effective pharmacological therapies. Herein, we proposed a novel approach to modulate the inflammation through metabolic remodeling, thus promoting dry …
Dry eye disease (DED) is a prevalent inflammatory condition significantly impacting quality of life, yet lacks effective pharm …
Thymosin beta 4 and the eye: the journey from bench to bedside.
Expert Opin Biol Ther. 2018 Jul;18(sup1):99-104. doi: 10.1080/14712598.2018.1486818.
Expert Opin Biol Ther. 2018.
PMID: 30063853
Review.
Thymosin beta 4 (Tbeta4) has important applications in ocular repair and Phase 3 clinical trials using Tbeta4 to treat dry eye and neurotrophic keratopathy are currently ongoing. ...Expert opinion: The electrifying possibility of Tbeta4 as a rev …
Thymosin beta 4 (Tbeta4) has important applications in ocular repair and Phase 3 clinical trials using Tbeta4 to treat …
Thymosin Beta 4: A Potential Novel Therapy for Neurotrophic Keratopathy, Dry Eye, and Ocular Surface Diseases.
Vitam Horm. 2016;102:277-306. doi: 10.1016/bs.vh.2016.04.012. Epub 2016 Jul 5.
Vitam Horm. 2016.
PMID: 27450739
Review.
Chronic ocular surface diseases such as dry eye, blepharitis, and neurotrophic keratopathies represent a significant and a growing therapeutic challenge. ...A focus on treatments that reduce the inflammatory responses while accelerating corneal epithelial growth wou …
Chronic ocular surface diseases such as dry eye, blepharitis, and neurotrophic keratopathies represent a significant and a gro …
Thymosin beta 4: A potential novel adjunct treatment for bacterial keratitis.
Int Immunopharmacol. 2023 May;118:109953. doi: 10.1016/j.intimp.2023.109953. Epub 2023 Apr 3.
Int Immunopharmacol. 2023.
PMID: 37018981
Free PMC article.
To this end, treatments are needed that both regulate the inflammatory response and promote corneal wound healing to resolve visual disturbances and improve quality of life. Thymosin beta 4 is a small, naturally occurring 43-amino-acid protein that promotes w …
To this end, treatments are needed that both regulate the inflammatory response and promote corneal wound healing to resolve visual disturba …
Thymosin beta4: a potential novel dry eye therapy.
Ann N Y Acad Sci. 2012 Oct;1270:45-50. doi: 10.1111/j.1749-6632.2012.06682.x.
Ann N Y Acad Sci. 2012.
PMID: 23050816
Review.
The purpose of this manuscript is to review the clinical entity of dry eye syndrome (DES) and to provide a scientific basis and rationale for the usage of thymosin beta 4 (Tbeta4) as a novel therapy for DES. ...Based on previous studies, there i …
The purpose of this manuscript is to review the clinical entity of dry eye syndrome (DES) and to provide a scientific basis an …
Primary Mechanisms of Thymosin beta4 Repair Activity in Dry Eye Disorders and Other Tissue Injuries.
Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5110-7. doi: 10.1167/iovs.15-16890.
Invest Ophthalmol Vis Sci. 2015.
PMID: 26241398
Review.
Dry eye disorders are becoming more common due to many causes, including an aging population, increased pollution, and postrefractive surgery. ...We will also speculate on additional mechanisms that might promote eye repair based on data from other tissue inj …
Dry eye disorders are becoming more common due to many causes, including an aging population, increased pollution, and postref …
Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE ) model.
Clin Ophthalmol. 2015 May 20;9:877-84. doi: 10.2147/OPTH.S80954. eCollection 2015.
Clin Ophthalmol. 2015.
PMID: 26056426
Free PMC article.
BACKGROUND: The purpose of this study was to evaluate the safety and efficacy of thymosin beta 4 ophthalmic solution (RGN-259; Tbeta4) in subjects with moderate to severe dry eye using the CAE model. ...CONCLUSION: This study confirms the effic …
BACKGROUND: The purpose of this study was to evaluate the safety and efficacy of thymosin beta 4 ophthalmic solution (R …
Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.
Cornea. 2015 May;34(5):491-6. doi: 10.1097/ICO.0000000000000379.
Cornea. 2015.
PMID: 25826322
Clinical Trial.
PURPOSE: Standard therapies for severe dry eye are limited and fail to resolve the problem. The purpose of this study was to evaluate the safety and efficacy of Thymosin beta4 eye drops (RGN-259) as a novel therapy for severe dry eye dise …
PURPOSE: Standard therapies for severe dry eye are limited and fail to resolve the problem. The purpose of this study was to e …
Thymosin beta(4) and beta(10) in Sjogren's syndrome: saliva proteomics and minor salivary glands expression.
Arthritis Res Ther. 2016 Oct 6;18(1):229. doi: 10.1186/s13075-016-1134-7.
Arthritis Res Ther. 2016.
PMID: 27716395
Free PMC article.
BACKGROUND: In the present study, we investigated whether thymosin beta (Tbeta) in saliva and in minor salivary glands is differentially expressed in patients with primary Sjogren's syndrome (pSS) and patients with autoimmune diseases (systemic sclerosis [SSc], systemic lu …
BACKGROUND: In the present study, we investigated whether thymosin beta (Tbeta) in saliva and in minor salivary glands is differentia …
Recombinant Human Thymosin beta4 (rhTbeta4) Modulates the Anti-Inflammatory Responses to Alleviate Benzalkonium Chloride (BAC)-Induced Dry Eye Disease.
Int J Mol Sci. 2022 May 13;23(10):5458. doi: 10.3390/ijms23105458.
Int J Mol Sci. 2022.
PMID: 35628276
Free PMC article.
Dry eye disease (DED) is a multifactorial ocular disorder that interferes with daily living and reduces quality of life. ...Eye drops consisting of 0.05% and 0.1% rhTbeta4 were used for treatment of DED. Tear volume and corneal staining scores were measured a …
Dry eye disease (DED) is a multifactorial ocular disorder that interferes with daily living and reduces quality of life. ... …
Cite